This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Against Blyth, Inc. (BTH), Align Technology, Inc. (ALGN) And Abiomed, Inc. (ABMD) And Investigation Of Peregrine Pharmaceuticals, Inc. (PPHM)

Stocks in this article: ABMDALGNBTHPPHM

NEW YORK, Dec. 5, 2012 /PRNewswire/ --

Blyth, Inc. Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the District of Connecticut on behalf of investors who purchased Blyth, Inc. (NYSE: BTH) stock between March 14, 2012 and November 6, 2012.

For more information, click here: http://zlk.9nl.com/blyth-bth .  You have until January 12, 2013 to request that the Court appoint you as lead plaintiff.

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

Align Technology, Inc. Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who acquired Align Technology, Inc. (NasdaqGS: ALGN) securities between April 23, 2012 and October 17, 2012.

For more information, click here: http://zlk.9nl.com/align-technology-algn/ . You have until January 28, 2013 to request that the Court appoint you as lead plaintiff.

Abiomed, Inc. Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Abiomed, Inc. (Nasdaq: ABMD) stock between August 5, 2011 and October 31, 2012.

For more information, click here: http://zlk.9nl.com/abiomed-abmd .  

Peregrine Pharmaceuticals, Inc. Levi & Korsinsky is investigating potential claims on behalf of purchasers of Peregrine Pharmaceuticals, Inc. (NasdaqCM: PPHM) securities concerning possible breaches of fiduciary duty in connection with the disclosure of the discovery of major discrepancies in the treatment group of its Bavituxmab Phase II Second-Line Non-Small Cell Lung Cancer Trial.

For more information, click here : http://zlk.9nl.com/peregrine-pharmaceuticals-pphm/ .  

Levi & Korsinsky is a national firm with offices in New York and Washington D.C.  The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:     Levi & Korsinsky, LLP Joseph Levi, Esq. Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free:  (877) 363-5972 Fax: (212) 363-7171 www.zlk.com 

SOURCE Levi & Korsinsky, LLP

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs